An investigation on behalf of investors in NASDAQ:ALXN shares over potential wrongdoing at Alexion Pharmaceuticals, Inc. was announced and NASDAQ:ALXN stockholders should contact the Shareholders Foundation.

San Diego, CA -- (SBWire) -- 11/15/2016 --An investigation was announced on behalf of investors in shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) over potential breaches of fiduciary duties by certain directors at Alexion Pharmaceuticals.

Investors who purchased shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call 858-779-1554.

The investigation by a law firm concerns whether certain Alexion Pharmaceuticals, Inc. directors breached their fiduciary duties and caused damage to the company and its shareholders.

On June 6, 2016, Alexion Pharmaceuticals, Inc announced topline results from Phase 3 REGAIN Study of Eculizumab (Soliris®) in patients with refractory generalized myasthenia gravis.

On November 9, 2016, Alexion Pharmaceuticals, Inc announced that the Audit and Finance Committee of the Board of Directors is conducting an investigation into allegations that recently have been made by a former employee with respect to the Company's sales practices of Soliris. Alexion Pharmaceuticals, Inc said that the Audit and Finance Committee is investigating whether Company personnel have engaged in sales practices that were inconsistent with Company policies and procedures and the related disclosure and other considerations raised by such practices and that the Audit and Finance Committee has retained outside counsel to assist it in the investigation.

Shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) declined on November 11, 2016 to $11.66 per share.

Those who purchased shares of Alexion Pharmaceuticals, Inc. have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com